Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?
European Journal of Neurology2016Vol. 24(2), pp. 237–244
Citations Over TimeTop 10% of 2016 papers
Abstract
In this retrospective study, including a limited number of patients with SPMS, the annualized relapse rate remained stable after treatment withdrawal, relative to before treatment withdrawal. Further prospective studies are needed to confirm this result and provide evidence-based guidelines for daily practice.
Related Papers
- → Altered frequency of T regulatory cells is associated with disability status in relapsing–remitting multiple sclerosis patients(2012)38 cited
- → MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS)(1999)20 cited
- → Expanded disability status scale in Multiple Sclerosis: Relationship to visual evoked potential(2022)2 cited
- → A non‐randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing‐remitting multiple sclerosis patients(2019)2 cited
- [Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b].(2013)